Articles by Jill Wechsler - Pharmaceutical Executive

ADVERTISEMENT

Articles by Jill Wechsler

Full Disclosure for Pharma

Apr 1, 2013

There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices.

Another Round of FDA Legislation?

Mar 1, 2013

Pressure for action on key enforcement and regulatory issues may prompt congressional action this year.

Breakthrough Year for New Drugs

Feb 1, 2013

More new medicines gained market approval in 2012, but marketers face resistance from payers looking to cut healthcare spending, writes Jill Wechsler.

Transformation to Characterize 2013

Jan 1, 2013

FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing.

Obamacare, Innovation and Pricing

Dec 1, 2012

Tax and budget decisions will shape the healthcare market and drug research and regulation.

Budgets, Biosimilars, and Bad Ads

Nov 1, 2012

While the nation was embroiled in the presidential elections, a number of important legal and regulatory issues absorbed pharmaceutical executives, writes Jill Wechsler.

Latest Changes and Challenges at FDA

Oct 1, 2012

New user fee programs precipitate major changes at an agency under constant and intense scrutiny, writes Jill Wechsler.

Costs, Coverage, and Court Decisions

Sep 1, 2012

Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare.

Fleshing Out FDASIA

Aug 1, 2012

Medical apps, e-submissions, counterfeit drugs, and imports tucked into fairly "clean" user-fee renewal legislation.

ADVERTISEMENT

Click here